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Simple Summary: Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA)
is an effective antitumor-treatment in metastatic castration-resistant prostate carcinoma (mCRPC).
Concerns of potential nephrotoxicity are based on renal tubular PSMA expression and the re-
sulting radiopharmaceutical retention during RLT, but data confirming clinically significant re-
nal toxicity are still lacking. In this study, n = 22 patients treated within a prospective patient
registry (REALITY Study) with significantly impaired baseline kidney function were investigated
for treatment-associated nephrotoxicity and the potential relationship with administered activities
of [177Lu]Lu-PSMA-617. As opposed to prevailing concerns, glomerular filtration rate (GFR) im-
proved significantly in our cohort of patients and no significant correlation between change in GFR
and administered activities were found. As pre-treatment chronic kidney failure did not lead to
detectable RLT-induced deterioration of renal function in our study, the nephrotoxic potential of
[177Lu]Lu-PSMA-617 RLT may be overestimated. We suggest not to categorically exclude patients
from enrolment to PSMA-RLT due to renal impairment.
Abstract: Background: Radioligand therapy (RLT) targeting prostate-specific membrane antigen
(PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate carcinoma
(mCRPC). Concerns of potential nephrotoxicity are based on renal tubular PSMA expression and the
resulting radiopharmaceutical retention during RLT, but data confirming clinically significant renal
toxicity are still lacking. In this study, patients with significantly impaired baseline kidney function
before initiation of therapy were investigated for treatment-associated nephrotoxicity and the poten-
tial relationship with administered activities of [177Lu]Lu-PSMA-617. Methods: Twenty-two mCRPC
patients with impaired renal function (glomerular filtration rate (GFR) ≤ 60 mL/min) who received
more than two cycles of [177Lu]Lu-PSMA-617 RLT (median 5 cycles and median 6-week time interval
between consecutive cycles) were analyzed in this study. Patients were treated within a prospective
patient registry (REALITY Study, NCT04833517). Cumulative administered activities ranged from
17.1 to 85.6 GBq with a median activity of 6.5 GBq per cycle. Renal function was closely monitored
during and after PSMA-RLT. Results: Mean pre-treatment GFR was 45.0 ± 10.7 mL/min. After two
(22/22 patients), four (20/22 patients), and six cycles (10/22 patients) of RLT, a significant increase
of GFR was noted (each p < 0.05). End-of-treatment GFR (54.1 ± 16.7 mL/min) was significantly
higher than baseline GFR (p = 0.016). Only one patient experienced deterioration of renal function
(change of CTCAE grade 2 to 3). The remaining patients showed no significant reduction of GFR,
including follow-up assessments (6, 9, and 12 months), and even showed improved (10/22 patients)
or unchanged (11/22 patients) CTCAE-based renal impairment grades during and after the end
of PSMA-RLT. No significant correlation between the change in GFR and per-cycle (p = 0.605) or
cumulative (p = 0.132) administered activities were found. Conclusions: As pre-treatment chronic
kidney failure did not lead to detectable RLT-induced deterioration of renal function in our study, the
nephrotoxic potential of [177Lu]Lu-PSMA-617 RLT may be overestimated and not of clinical priority
in the setting of palliative treatment in mCRPC. We suggest not to categorically exclude patients from
enrolment to PSMA-RLT due to renal impairment.
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1. Introduction
Besides established chemotherapy with taxanes (docetaxel, cabazitaxel) [1–3] and
treatment with novel androgen axis drugs (NAAD) (abiraterone or enzalutamide) [4,5], ra-
dioligand therapy targeting the prostate-specific membrane antigen (PSMA) is a promising
therapy option in metastatic castration-resistant prostate carcinoma (mCRPC) [6,7]. PSMA
is a transmembrane glycoprotein, which is largely overexpressed on the cell surface of
prostate cancer cells [8]. Its overexpression and endocytosis after radioligand binding to
the protein makes PSMA a specific target offering new ways of imaging and treatment of
prostate carcinoma [9,10]. PSMA-targeted radioligand therapy (PSMA-RLT) with [177Lu]Lu-
PSMA-617 has shown promising results in various recent studies [11–15]. Adverse effects
seem to be rare and related to irradiation of non-target tissue due to the physiologic PSMA
expression in healthy organs, such as the salivary glands and the kidneys. One observed
adverse effect is xerostomia negatively affecting the quality of life without being life threat-
ening. Physiological PSMA expression in the cells of the proximal renal tubules could
potentially lead to more serious complications. However, despite the high tracer accumula-
tion in the kidneys, little has been reported on the renal toxicity of PSMA-RLT, which could
be explained by the fact that most patients receive PSMA-RLT as a last-option treatment,
and therefore, long follow-up data are rare. Nevertheless, higher grades of nephrotoxicity,
i.e., grade ≥ 3, defined by common terminology criteria for adverse effects (CTCAE), seem
not to occur in patients with normal renal function [16]. Yet, there is no study investigating
nephrotoxicity in patients with renal impairment before commencement of PSMA-RLT,
although renal impairment is not uncommon in advanced mCRPC settings and can result
from nephrotoxic effects of previous androgen deprivation therapy (ADT) or taxane-based
chemotherapy [17,18]. In addition, obstruction of the urinary tract by excessive iliac and
retroperitoneal tumor masses may also lead to obstructive nephropathy with reduced renal
function [19].
In this study, we investigated treatment-associated nephrotoxicity and its potential
relationship with administered activities of [177Lu]Lu-PSMA-617 in mCRPC patients with
impaired renal function at baseline, i.e., before commencement of PSMA-RLT.
2. Methods
In this study, n = 22 consecutive mCRPC patients with markedly impaired renal
function, who received more than two cycles of [177Lu]Lu-PSMA-617 RLT in the palliative
setting were analyzed. Patients were treated at our institution within a prospective pa-
tient registry (REALITY Study, NCT04833517). Impaired renal function was defined as a
glomerular filtration rate (GFR) ≤ 60 mL/min [20]. GFR was estimated using the MDRD
formula [21]. All patients had high tumor burden and had received various conventional
treatments prior to PSMA-RLT, including ADT, NAAD, and chemotherapy. Table 1 presents
the detailed patient characteristics.
PSMA-RLT was performed on a compassionate use basis under the German Phar-
maceutical Act §13 (2b). All patients gave their written consent after being thoroughly
informed about the risks and side effects of this new therapy and consented to publication
of their data in accordance with the declaration of Helsinki. The study was approved by
the local Institutional Review Board (ethics committee permission number 140/17).
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Table 1. Patient characteristics.
Patient Characteristics Value Percentage/Range
Number of patients 22
Age
Median (range) in years 77 (61–88)
≥75 years—n (%) 13 (59.1)
Sites of metastases—n (%)
Bone 21 (95.5)
Lymph node 16 (72.7)
Liver 7 (31.8)
Baseline PSA







GFR at baseline—n (%)
≤60 mL/min 22 (100)
>40 to ≤60 mL/min 15 (68.2)
≤40 mL/min 7 (31.8)
PSA (prostate-specific antigen), GFR (glomerular filtration rate).
The radioligand [177Lu]Lu-PSMA-617 was administered during an inpatient stay in
accordance with German radiation protection regulations. Each patient received intra-
venous hydration (500 mL 0.9% NaCl) and cooling of the salivary glands, starting 30 min
prior to treatment infusion. The [177Lu]Lu-PSMA-617 solution was intravenously admin-
istered by infusion line over a period of 1 h. No diuretics (except in patients with heart
failure-related fluid restrictions) or other renal protection were applied. The patients were
treated by PSMA-RLT with a median of five cycles (range: 3–14) and with a median time
interval of 6 weeks between consecutive cycles. The administered activity ranged from
3.1 to 10.9 GBq per cycles (median and mean 6.5 GBq). The total administered activity of
[177Lu]Lu-PSMA-617 ranged from 17.1 to 85.6 GBq (median 36.2 GBq, mean 40.1 GBq).
Detailed information about the individual PSMA-RLT course of each patient is presented
in the Supplementary Material (Figure S1). Renal function was closely monitored during
and after PSMA-RLT. The median follow-up time was 10 months (range 3–24 month). For
statistical analysis, Wilcoxon matched-pairs signed rank test, Spearman correlation, and
Fisher’s exact test were applied using Prism 8 (GraphPad Software, San Diego, CA, USA).
A p-value < 0.05 was regarded as statistically significant.
3. Results
In the cohort of n = 22 mCRPC patients included in this study, the mean baseline
GFR before commencement of PSMA-RLT was 45.0 ± 10.7 mL/min. After two, four, and
six cycles of [177Lu]Lu-PSMA-617 RLT, no decrease, but a significant increase of renal
function was observed (Figure 1). After two cycles, GFR was 52.0 ± 17.4 mL/min (vs.
45.0 ± 10.7 mL/min at baseline, p = 0.041). In total, 20/22 (91%) and 10/22 (45%) patients
received at least four and six cycles of PSMA-RLT, respectively. In these patients (n = 20
and n = 10), GFR was 55.6 ± 18.8 after four cycles (vs. 44.4 ± 11.0 mL/min at baseline,
p = 0.007) and 61.8 ± 20.4 mL/min after six cycles (vs. 43.3 ± 9.3 mL/min at baseline,
p = 0.022), respectively. A representative example is given in Figure 2, showing an increase
in GFR after four cycles of PSMA-RLT, concordant with marked reduction of tumor burden
and improvement of the patient’s condition.
Cancers 2021, 13, 3095 4 of 10
Cancers 2021, 13, 3095 4 of 10 
 
 
least four and six cycles of PSMA-RLT, respectively. In these patients (n = 20 and n = 10), 
GFR was 55.6 ± 18.8 after four cycles (vs. 44.4 ± 11.0 mL/min at baseline, p = 0.007) and 61.8 
± 20.4 mL/min after six cycles (vs. 43.3 ± 9.3 mL/min at baseline, p = 0.022), respectively. A 
representative example is given in Figure 2, showing an increase in GFR after four cycles 
of PSMA-RLT, concordant with marked reduction of tumor burden and improvement of 
the patient’s condition. 
 
Figure 1. Comparison of GFR at baseline and after two cycles (A), four cycles (B), and six cycles (C) of [177Lu]Lu-PSMA-
617 RLT. 
 
Figure 2. Advanced mCRPC patient with reduced condition and impaired renal function before commencement of PSMA-
RLT. The patient received four cycles of [177Lu]Lu-PSMA-617. While marked tumor regression and improvement of the 
patient’s condition was observed, GFR increased from 25 mL/min at baseline to 37 mL/min after the end of [177Lu]Lu-
PSMA-617 RLT. This improvement of renal function can also be seen on [68Ga]Ga-PSMA-11 PET imaging with an increased 
tracer uptake in the single left kidney (red arrow). The patient had a history of right kidney resection due to renal cell 
carcinoma. 
After two cycles of PSMA-RLT, 16/22 (72.7%) patients showed partial remission with 
a PSA decline >50% and 5/22 (22.7%) showed stable disease with a PSA change between 
Figure 1. Co parison of GFR at baseline and after two cycles (A), four cycles (B), and six cycles (C) of [177Lu]Lu-PSMA-617 RLT.
Cancers 2021, 13, 3095 4 of 10 
 
 
least four and six cycles of PSMA-RLT, respectively. In these patients (n = 20 and n = 10), 
GFR was 55.6 ± 18.8 after four cycles (vs. 44.4 ± 11.0 mL/min at baseline, p = 0.007) and 61.8 
± 20.4 mL/min after six cycles (vs. 43.3 ± 9.3 mL/min at baseline, p = 0.022), respectively. A 
representative example is given in Figure 2, showing an increase in GFR after four cycles 
of PSMA-RLT, concordant with marked reduction of tumor burden and improvement of 
the patient’s condition. 
 
Figure 1. Comparison of GFR at baseline and after two cycles (A), four cycles (B), and six cycles (C) of [177Lu]Lu-PSMA-
617 RLT. 
 
Figure 2. Advanced mCRPC patient with reduced condition and impaired renal function before commencement of PSMA-
RLT. The patient received four cycles of [177Lu]Lu-PSMA-617. While marked tumor regression and improvement of the 
patient’s condition was observed, GFR increased from 25 mL/min at baseline to 37 mL/min after the end of [177Lu]Lu-
PSMA-617 RLT. This improvement of renal function can also be seen on [68Ga]Ga-PSMA-11 PET imaging with an increased 
tracer uptake in the single left kidney (red arrow). The patient had a history of right kidney resection due to renal cell 
carcinoma. 
After two cycles of PSMA-RLT, 16/22 (72.7%) patients showed partial remission with 
a PSA decline >50% and 5/22 (22.7%) showed stable disease with a PSA change between 
A B C
p = 0.041 p = 0.007 p = 0.022
baseline after 2 cycles after 4 cycles
3 x SUVmean 
liver
0
PSA: 120 ng/mL PSA: 10 ng/mL PSA: 3 ng/mL
Figure 2. Advanced mCRPC patient with reduced condition and impaired renal function before commencement of PSMA-
T. The patient received four cycles of [177 ] - S -617. ile ar e t r re ressi a i r e e t f t e
atie t’s con iti as observed, GFR increased from 25 mL/ i at baseline to 37 mL/ ft t e end of [17
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After two cycles of PSMA-RLT, 16/22 (72.7%) patients showed partial remission with
a PSA decline >50% and 5/22 (22.7%) showed stable disease with a PSA change between
−50% and +25%. Only one patient (4.5%) exhibited progressiv isease after tw cycles
with a PSA increase >25%. In the following course, PSMA-RLT w s discontinued du to
remission in 8/22 (36.4%) patients after a median of four cycles or ended by death in the re-
maining 14/22 (63.6%) patients due to eventual tumor progression after a median of seven
cycles. The GFR at the end of therapy after median of five cycles (range: 3–14, Figure S1)
was 54.1 ± 16.7 mL/min and significantly higher compared to baseline GFR (p = 0.016)
(Figure 3A). A mean GFR increase of +25.3 ± 36.5% was observed. The individual change
in GFR of each patient after the last cycle of PSMA-RLT is depicted in Figure 3B. Only one
patient (4.5%) revealed a marked GFR decrease (−34.1%) associated with a deterioration
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of CTCAE grade 2 to grade 3. This patient was of advanced age (88 years), heavily pre-
treated, and in impaired general condition. The patient started PSMA-RLT with a GFR
of 44 mL/min (CTCAE 2), which slowly decreased to 29 mL/min (CTCAE 3) during the
course of PSMA-RLT. After an initial biochemical partial response, PSA progression was
observed during the course of PSMA-RLT, and the patient died within a short time after
the seventh cycle. In all other patients, renal function impairment according to CTCAE
grading either decreased (n = 10, 45.5%) or remained unchanged (11/22, 50.0%) during
and after the end of PSMA-RLT. All CTCAE grades are summed in Table 2.
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the mean administered activity per cycle (r = −0.117; p = 0.605, Figure 5A) or the total
cumulated administered activity (r = 0.332; p = 0.132, Figure 5B) were found. Even in
patients receiving cumulative activities of more than 35 GBq [177Lu]Lu-PSMA-617 (n = 12),
no significant change of GFR was observed (p = 0.304, Figure 5C).




Figure 4. Comparison of GFR at baseline and at follow-up after 6 months (A), 9 months (B), and 12 months (C). 
To analyze the dependency of renal function on the applied activity, correlation anal-
yses were performed. No significant correlations between the change in GFR and the 
mean administered activity per cycle (r = −0.117; p = 0.605, Figure 5A) or the total cumu-
lated administered activity (r = 0.332; p = 0.132, Figure 5B) were found. Even in patients 
receiving cumulative activities of more than 35 GBq [177Lu]Lu-PSMA-617 (n = 12), no sig-
ifica t change of GFR was observed (p = 0.304, Figure 5C). 
 
Figure 5. Correlation of the mean administered activity of [177Lu]Lu-PSMA-617 per cycle (p.c.) and the change in GFR per 
cycle (p.c.) (A). Correlation of the total administered activity of [177Lu]Lu-PSMA-617 and change in GFR (B). Comparison 
of GFR in patients receiving more than 35 GBq [177Lu]Lu-PSMA-617 (C). 
4. Discussion 
PSMA-RLT is a very effective treatment modality for advanced mCRPC patients with 
potential nephrotoxicity due to physiological PSMA expression in the renal tubular cells 
and consecutive radiopharmaceutical binding and retention. Reported absorbed renal 
doses in PSMA-RLT with 177Lu are significant and range between 0.4 and 1.0 Gy/GBq [22–
27]. However, limited data are available regarding long-term nephrotoxicity of PSMA-
RLT, especially in patients with impaired renal function at baseline before initiation of 
radionuclide therapy. We performed this retrospective analysis on renal function changes 
in a selected cohort of n = 22 mCRPC patients with markedly impaired baseline renal func-
tion receiving a median of five RLT cycles with a mean total administered of 40.1 GBq 
[177Lu]Lu-PSMA-617. This is the first PSMA-RLT study regarding the potential nephrotox-
icity in a relevant cohort of patients with this grade of compromised baseline renal func-
tion and subsequent treatment with high cumulative activities. The analysis reveals that 
even in these patients the nephrotoxic potential seems to be largely overestimated. 
As opposed to prevailing concerns on potential RLT-induced renal toxicity, GFR im-
proved significantly in our cohort of patients with renal impairment (after two, four, and 
A B C
p = 0.019 p = 0.236p = 0.070
Figure 5. Correlation of the mean administered activity of [177Lu]Lu-PSMA-617 per cycle (p.c.) and the change in GFR per
cycle (p.c.) (A). Correlation of the total administered activity of [177Lu]Lu-PSMA-617 and change in GFR (B). Comparison of
GFR in patients receiving more than 35 GBq [177Lu]Lu-PSMA-617 (C).
4. Discussion
PSMA-RLT is a very effective treatment modality for advanced mCRPC patients with
potential nephrotoxicity due to physiological PSMA expression in the renal tubular cells and
consecutive radiopharmaceutical binding and retention. Reported absorbed renal doses
in PSMA-RLT with 177Lu are significant and range between 0.4 and 1.0 Gy/GBq [22–27].
However, limited data are available regarding long-term nephrotoxicity of PSMA-RLT,
especially in patients with impaired renal function at baseline before initiation of radionu-
clide therapy. We performed this retrospective analysis on renal function changes in a
selected cohort of n = 22 mCRPC patients with markedly impaired baseline renal function
receiving a median of five RLT cycles with a mean total administered of 40.1 GBq [177Lu]Lu-
PSMA-617. This is the first PSMA-RLT study regarding the potential nephrotoxicity in a
relevant cohort of patients with this grade of compromised baseline renal function and
subsequent treatment with high cumulative activities. The analysis reveals that even in
these patients the nephrotoxic potential seems to be largely overestimated.
As opposed to prevailing concerns o potential RLT-induced r nal toxicity, GFR
improved significantly in our hort of patients with renal impairment (after two, four,
and six cycles and at the end of therapy), seemingly due to the overall improvement of
patients’ condition. Twelve patients (54.5%) experienced a significant improvement of
overall condition during PSMA-RLT documented after two cycles (i.e., when patients were
admitted to our therapy ward for the third treatment cycle). A significant improvement
of GFR (i.e., change in GFR ≥ 20%) at this time point was statistically associated with
clinical improvement (p = 0.031, Fisher’s exact test). Additionally, a high PSA response
rate (72.7% after two cycles) was noted at this time point in our cohort; however, there was
no statistically significant association with the improvement of GFR (p = 0.351, Fisher’s
exact test); furthermore, there was no correlation between the relative changes in PSA
and GFR (r = −0.142, p = 0.529). Only in one patient (4.5%), a marked decrease of GFR
was noted with a CTCAE-based grade of renal impairment increasing from grade 2 to
3. All other patients showed either unchanged (11/22, 50%) or lower CTCAE (10/22,
45.5%) grades of renal insufficiency at the end of therapy when compared to pre-RLT
grades. Additionally, in the follow-up period of 12 months, no significant reduction of
GFR was observed. Other studies have shown a similar neglectable negative impact on
renal function in patient cohorts with better baseline renal function [28,29]. Zhang et al.
observed that [177Lu]Lu-PSMA-617 RLT is well tolerated in patients (n = 16, 2–6 cycles)
with a single functioning kidney without any appearance of CTCAE grade 3 or 4 [28]. Only
three patients from this cohort fulfilled the selection criterion of our study, i.e., baseline
Cancers 2021, 13, 3095 7 of 10
GFR ≤ 60 mL/min, with no significant reduction seen during follow-up. Yordanova et al.
reported no renal impairment or at maximum a slight decrease of GFR from a mixed
group of patients (n = 55, 3–6 cycles). Only eight patients from this cohort had a reduced
baseline GFR as required for inclusion in our study [29]. Additionally, in patients with
normal renal function, no relevant nephrotoxicity was reported in various retrospective
monocenter studies with a limited number of cycles and patients [11–13] and in a larger
German multicenter study (n = 145) [14]. This is consistent with the results of the Australian
prospective phase II trial (initially n = 30) by Hofman et al. [15] and its expanded trial
report with n = 50 patients [16]; their data of adverse effects were limited to a three-month
follow-up. From a longer follow-up observation report by Gallyamov et al. with a median
of 12 months from start of treatment, the incidence of renal impairment CTCAE grade 1 or
2 is expected to be below 5% [30].
Analogies can also be seen in studies on peptide-receptor-mediated radionuclide
therapy (PRRT) in patients with neuroendocrine tumor (NET). There is no acute renal toxi-
city in patients with metastasized NET [31] when treated with 177Lu-labeled somatostatin
analogues, including patients with a single functioning kidney [32]. Bodei et al. reported,
in a study with n = 807 patients, that long term renal impairment was infrequent and
especially rare when the radionuclide 177Lu was used, as compared to 90Y or combinations
of both [33].
Our results do not indicate a relationship between the amount of administered per-
cycle activity and renal adverse effects as the outcome with regard to renal function did
not differ among varying applied treatment activities. This may be seen in line with Seifert
et al., who observed no increase of renal side effects whether administering single activities
of 6.0 GBq versus 7.5 GBq [177Lu]Lu-PSMA-617 per cycle [34]. In our study, even high
cumulative activities >35 GBq (up to 85 GBq) were safe and did not lead to further decline
of pretreatment-compromised renal function.
These promising results underline that [177Lu]Lu-PSMA-617 RLT is associated with a
low nephrotoxic potential, even in patients with reduced renal function before initiation
of therapy, and even after administration of high cumulative activities in chronic kidney
function impairment. However, those patients with chronic renal disease are currently
excluded from PSMA-RLT in prospective studies, such as the current phase III VISION
trial [35]. In addition, regional treatment guidance, such as the German consensus recom-
mendations [36], advise very restricted use of PSMA-RLT in these patients, which may
often lead to preclusion of mCRPC patients from a potentially very successful antitumor
treatment. Based on the results of the present retrospective study, we recommend not
excluding patients from PSMA-RLT due to renal impairment.
The results reported herein should be considered in the light of some limitations.
Our study suffers from the retrospective nature and the small number (n = 22) of patients.
Another limiting factor is the heterogeneity of the treatment protocol applied to the patients
studied, in terms of inequality of therapy dose, number of cycles, and interval between
cycles. However, in the absence of published data, this report represents the first relevant
renal outcome series of PSMA-RLT in significantly impaired baseline renal function. A
further limitation is the lack of analysis of other renal parameters such as cystatin C, which
might be superior in calculating GFR or of consecutive renal scintigraphy. Larger studies,
ideally in prospective settings, investigating long-term safety of [177Lu]Lu-PSMA-617 RLT
in patients with impaired renal function, are necessary to address the important issue
of how to handle chronic renal failure as an exclusion criterion for this important new
treatment modality.
5. Conclusions
Nephrotoxic potential of [177Lu]Lu-PSMA-617 RLT seems to be largely overestimated,
even in mCRPC patients with impaired renal function. In our cohort of mCRPC patients
with pre-treatment chronic renal failure or renal function impairment, we observed no RLT-
induced negative impact on renal function. Therefore, patients should not be categorically
Cancers 2021, 13, 3095 8 of 10
excluded from enrolment to PSMA-RLT due to renal impairment. From our experience,
even high cumulative activities of [177Lu]Lu-PSMA-617 seem to be well tolerated, with no
significant impact on renal function. Ideally, to support the conclusion, all patients with
impaired renal function should be treated with a standardized, adapted protocol, which
still has to be defined.
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